ProShare Advisors LLC lifted its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 40.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 40,875 shares of the company's stock after acquiring an additional 11,729 shares during the quarter. ProShare Advisors LLC's holdings in Vaxcyte were worth $3,346,000 at the end of the most recent reporting period.
Several other institutional investors have also recently made changes to their positions in PCVX. Nisa Investment Advisors LLC lifted its holdings in shares of Vaxcyte by 21.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,684 shares of the company's stock worth $220,000 after acquiring an additional 475 shares during the last quarter. Avior Wealth Management LLC increased its stake in Vaxcyte by 21.1% in the 4th quarter. Avior Wealth Management LLC now owns 6,456 shares of the company's stock worth $528,000 after buying an additional 1,124 shares during the period. Blue Trust Inc. increased its stake in Vaxcyte by 125.1% in the 4th quarter. Blue Trust Inc. now owns 835 shares of the company's stock worth $68,000 after buying an additional 464 shares during the period. KBC Group NV increased its stake in Vaxcyte by 78.0% in the 4th quarter. KBC Group NV now owns 4,775 shares of the company's stock worth $391,000 after buying an additional 2,092 shares during the period. Finally, Chicago Partners Investment Group LLC increased its stake in Vaxcyte by 9.2% in the 4th quarter. Chicago Partners Investment Group LLC now owns 5,431 shares of the company's stock worth $440,000 after buying an additional 458 shares during the period. Institutional investors own 96.78% of the company's stock.
Vaxcyte Trading Down 4.2%
Shares of NASDAQ:PCVX traded down $1.41 during trading on Friday, reaching $32.54. The stock had a trading volume of 1,763,863 shares, compared to its average volume of 1,371,448. Vaxcyte, Inc. has a one year low of $27.66 and a one year high of $121.06. The company has a market capitalization of $4.20 billion, a P/E ratio of -7.07 and a beta of 1.27. The firm's 50-day simple moving average is $38.53 and its 200 day simple moving average is $68.96.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). During the same quarter last year, the company posted ($0.85) EPS. Equities research analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
PCVX has been the topic of several recent analyst reports. Guggenheim reaffirmed a "buy" rating and issued a $160.00 price target on shares of Vaxcyte in a research note on Wednesday, March 12th. Bank of America cut their target price on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. The Goldman Sachs Group cut their target price on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Cantor Fitzgerald initiated coverage on shares of Vaxcyte in a research report on Tuesday, April 22nd. They set an "overweight" rating on the stock. Finally, Needham & Company LLC reissued a "buy" rating and set a $90.00 target price on shares of Vaxcyte in a research report on Tuesday, April 8th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $136.50.
Read Our Latest Stock Report on PCVX
Insider Buying and Selling
In other news, COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $73.27, for a total transaction of $586,160.00. Following the completion of the transaction, the chief operating officer now directly owns 154,931 shares of the company's stock, valued at $11,351,794.37. The trade was a 4.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 3.10% of the stock is owned by company insiders.
About Vaxcyte
(
Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Featured Stories
Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
